Table 1 Patients’ clinical and pathological features
Clinicopathological Variables | Z0011 group n = 67 (%) | Z0011-eligible group n = 126 (%) |
|---|---|---|
Age(years) | ||
< 50 ≥ 50 | 20(29.9) 47(70.1) | 37 (29.4) 89 (70.6) |
T-stage | ||
T1 T2 | 25 (37.3) 42 (62.7) | 43 (34.1) 83 (65.9) |
Tumor localization | ||
Upper Outer Quadrant Upper Inner Quadrant Lower Inner Quadrant Lower Outer Quadrant Central | 33 (49.3) 18 (26.9) 4 (6.0) 5 (7.5) 8 (11.9) | 59 (46.8) 25 (19.8) 14 (11.1) 17 (13.5) 11 (8.7) |
Histopathological outcome | ||
NST Lobular Others | 59 (88) 4 (6) 4 (6) | 97 (77) 12 (9.5) 17 (13.5) |
Grade | ||
Grade 3 Grades 1 and 2 | 30 (44.8) 37 (55.2) | 65 (51.6) 61 (48.4) |
Hormone receptor | ||
Negative Positive | 7 (10.4) 60 (89.6) | 13 (10.3) 113 (89.7) |
ER | ||
Negative Positive | 7 (10.4) 60 (89.6) | 13 (10.3) 113 (89.7) |
PR | ||
Negative Positive | 8 (11.9) 59 (88.1) | 16 (12.7) 110 (87.3) |
Ki-67 (mean) | 35.34 ± 20.13 | 36.73 ± 22.44 |
Ki-67 | ||
≤ 14 > 14 | 5 (7.5) 62 (92.5) | 14 (11.2) 111 (88.8) |
HER-2 status | ||
Negative Positive | 60 (89.6) 7 (10.4) | 107 (84.9) 19 (15.1) |
Presence of perineural invasion | ||
No Yes | 56 (83.6) 11 (16.4) | 94 (74.6) 32 (25.4) |
Presence of lymphovascular invasion | ||
No Yes | 46 (68.7) 21 (31.3) | 80 (63.5) 46 (36.5) |
Localization | ||
unifocal multifocal | 65 (97) 2 (3) | 118 (93.7) 8 (6.3) |
Adjuvant chemotherapy | ||
No Yes | 2 (3) 65 (97) | 3 (2) 123 (98) |
Adjuvant endocrine therapy | ||
No Yes | 9 (13) 58 (87) | 15 (12) 111 (88) |
RT Localization | ||
Whole-Breast Alone Level I/II Nodal Radiotherapy | 5 (7.5) 8 (11.9) 54 (80.6) | 15 (11.9) 26 (20.6) 85 (67.5) |
Radiotherapy | ||
No Yes | 0 67 (100) | 0 126 (100) |